NASDAQ$ACAD
ACADIA Pharmaceuticals Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Acadia Pharmaceuticals reported an increase in NUPLAZID net sales and reiterated its full-year net sales guidance. However, the company received Complete Response Letters from the FDA regarding its sNDA for NUPLAZID in dementia-related psychosis.
Acadia Pharmaceuticals reported a net sales increase for NUPLAZID in Q1 2021, reaching $106.6 million, an 18% increase compared to Q1 2020. The company is reiterating its full-year net sales guidance of $510 to $550 million. However, they also received Complete Response Letters from the FDA regarding their sNDA for NUPLAZID for dementia-related psychosis.
- NUPLAZID net sales were $106.6 million, an 18% increase over 1Q20.
- The company received Complete Response Letters from the FDA regarding its sNDA for NUPLAZID in dementia-related psychosis (DRP).
- Top-line results from the Phase 3 LAVENDER study evaluating trofinetide for the treatment of Rett syndrome are expected in the fourth quarter of 2021.
- Acadia is reiterating its NUPLAZID net sales guidance of $510 to $550 million for the year.
Headline financials
Revenue & EPS history
ACADIA · Revenue · Quarterly
$107M
Revenue by segment
ACADIA · $107M total across 1 segment · Q1 2021
- NUPLAZID$107M+18.3%100.0%
Forward guidance
Acadia is reiterating its NUPLAZID net sales guidance of $510 to $550 million. GAAP R&D guidance is decreased to $280 to $300 million from the previous range of $300 to $320 million. GAAP SG&A guidance is decreased to $385 to $415 million from the previous range of $560 to $590 million.
Tailwinds
- Reiterating NUPLAZID net sales guidance of $510 to $550 million.
- GAAP R&D guidance decreased to $280 to $300 million.
- GAAP SG&A guidance decreased to $385 to $415 million.
- Positive signs in the Parkinson’s disease psychosis market supporting revenue growth for the remainder of the year.
- Anticipate continued improvements in the conditions related to the pandemic.
Headwinds
- Received a Complete Response Letter (CRL) from the FDA regarding its sNDA for NUPLAZID for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP).
- Uncertainty of future commercial sales.
- Risks and uncertainties inherent in drug development, approval and commercialization.
- Past results of clinical trials may not be indicative of future trial results.
- The company is still operating at a net loss.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
-0.9%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-1.6%
Avg return
30 days after
42%
27 / 65 earnings
Positive
+23.7%
Q3 2016
Best reaction
-22.9%
Q4 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.9% | -2.5% | -3.6% | |
| Q4 2025 | -1.4% | -9.9% | -16.9% | |
| Q3 2025 | -2.9% | +6.2% | +22.9% | |
| Q1 2025 | +14.4% | +16.1% | +48.4% | |
| Q4 2024 | +1.8% | -3.9% | -10.2% | |
| Q3 2024 | +14.7% | +21.8% | +15.2% | |
| Q2 2024 | -17.6% | -15.1% | -11.9% | |
| Q1 2024 | -11.8% | -12.0% | -13.7% | |
| Q4 2023 | -8.3% | -7.3% | -28.6% | |
| Q3 2023 | +5.0% | +2.5% | -1.4% | |
| Q2 2023 | -6.0% | -7.4% | -4.0% | |
| Q1 2023 | -2.3% | -2.1% | +12.3% | |
| Q4 2022 | +9.4% | +7.5% | +0.3% | |
| Q3 2022 | -6.6% | -8.6% | -0.6% | |
| Q2 2022 | -1.3% | -0.2% | +2.5% | |
| Q1 2022 | -4.9% | -17.3% | -9.6% | |
| Q4 2021 | -2.2% | -6.2% | -4.8% | |
| Q3 2021 | +7.7% | +3.1% | +8.8% | |
| Q2 2021 | -11.0% | -11.4% | -22.4% | |
| Q1 2021 | +7.3% | +7.7% | +21.4% | |
| Q4 2020 | -4.9% | -0.4% | -48.0% | |
| Q3 2020 | +4.2% | +7.4% | +16.4% | |
| Q2 2020 | +0.3% | -5.1% | -12.1% | |
| Q1 2020 | +5.3% | +2.5% | -5.3% | |
| Q4 2019 | -3.9% | +7.6% | -4.5% | |
| Q3 2019 | +0.4% | +0.4% | +7.2% | |
| Q2 2019 | +14.7% | +14.4% | +10.6% | |
| Q1 2019 | +6.0% | +11.4% | -0.2% | |
| Q4 2018 | +7.5% | +12.0% | +12.2% | |
| Q3 2018 | -7.7% | -12.9% | -12.7% | |
| Q2 2018 | -2.0% | +0.7% | -1.1% | |
| Q1 2018 | +15.6% | +15.8% | +14.3% | |
| Q4 2017 | -22.9% | -26.8% | -30.5% | |
| Q3 2017 | -9.6% | -12.1% | -7.6% | |
| Q2 2017 | +8.6% | +2.1% | +17.1% | |
| Q1 2017 | -8.6% | -8.7% | -17.8% | |
| Q4 2016 | -8.1% | -7.4% | -14.4% | |
| Q3 2016 | +23.7% | +32.8% | +24.9% | |
| Q2 2016 | -1.8% | -10.3% | -15.0% | |
| Q1 2016 | +0.4% | — | — | |
| Q4 2015 | +2.2% | — | — | |
| Q3 2015 | -13.1% | — | — | |
| Q2 2015 | -17.8% | — | — | |
| Q1 2015 | +3.2% | — | — | |
| Q4 2014 | +1.5% | — | — | |
| Q3 2014 | -0.7% | — | — | |
| Q2 2014 | +3.1% | — | — | |
| Q1 2014 | -8.4% | — | — | |
| Q4 2013 | -4.8% | — | — | |
| Q3 2013 | -7.8% | — | — | |
| Q2 2013 | -5.6% | — | — | |
| Q1 2013 | -4.4% | — | — | |
| Q4 2012 | -6.0% | — | — | |
| Q3 2012 | +11.0% | — | — | |
| Q2 2012 | -0.7% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +0.6% | — | — | |
| Q4 2009 | +0.6% | — | — | |
| Q3 2011 | -5.0% | — | — | |
| Q4 2010 | -2.9% | — | — | |
| Q2 2011 | -2.9% | — | — | |
| Q1 2011 | -4.1% | — | — | |
| Q3 2010 | +1.4% | — | — | |
| Q2 2010 | -7.5% | — | — | |
| Q1 2010 | +11.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro